BioNJ welcomes Aerie Pharmaceuticals, Inc., and Archimedes Pharma as new Core Members for 2012.
Aerie Pharmaceuticals, Inc.
Aerie Pharmaceuticals is a privately held, clinical-stage biotechnology company dedicated to the discovery and development of novel treatments for glaucoma. All technology of the company is based on internal discovery R&D and is protected by a strong IP portfolio.
Aerie is developing a diverse portfolio of proprietary molecules for ophthalmic use from internal discovery, academia, and industry. In addition, Aerie optimizes delivery of medications to ocular target tissues and enhances patient compliance by developing novel, sustained drug-delivery solutions.
Our proven core competencies include ophthalmology, medicinal chemistry, cell biology, and pharmacology.
Archimedes Pharma is an international specialty pharmaceutical company providing novel and advanced treatments to address unmet needs for people living with serious or life-threatening chronic and debilitating illnesses. Marketing a diverse portfolio of specialty products in the oncology, pain, and critical care sectors, Archimedes Pharma has operations in the United States and Europe.
Founded in 2004, Archimedes Pharma acquired a range of specialty products and technologies, together with a commercial pharmaceutical platform to establish itself in the European market. In 2010, Archimedes Pharma opened its U.S. operations in New Jersey and has recently launched its first U.S. product, Lazanda.
For more information, visit Archimedes Pharma’s website.
BioNJ thanks Merck & Company for renewing its Diamond Membership for 2012.
Merck & Co., Inc.
Merck is a global research-driven pharmaceutical company that discovers, develops, manufactures, and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but also help deliver them to the people who need them.
BioNJ thanks United Parcel Service for renewing its Platinum Membership for 2012.
United Parcel Service
United Parcel Service (UPS) is a global leader in logistics, offering a broad range of solutions including the transportation of packages and freight, the facilitation of international trade, and the deployment of advanced technology to more efficiently manage the world of business. For the healthcare industry, UPS is equipped with specialized capabilities ranging from temperature-controlled warehousing and transportation services to regulatory compliance expertise and sophisticated monitoring technology. For information about UPS’s healthcare services, visit their website.
BioNJ thanks AcquiSci, Inc., AlfaGene Bioscience, Allos Therapeutics, Inc., and Prolong Pharmaceuticals LLC for renewing their Core Memberships for 2012.
AcquiSci, Inc., is developing its medical device-based platform technology, d-OSAB for the treatment of inflammatory-based diseases, such as stroke and chronic heart failure. Additional platform applications include a purification process for the production of pathogen-free biologics, i.e., the inactivation of infectious prions, the protein attributed to Mad Cow and Creutzfeldt-Jacob diseases. AcquiSci’s medical device d-OSAB comprises both equipment and dedicated disposable fluid contact device components. For biofluid purification, on a commercial basis, it is anticipated that all componentry will be fixed and reusable.
AlfaGene Bioscience is a prime source of genomics and proteomics products for biopharmaceutical industries and research institutions. The company can give expert advice and customized services to fit any client’s project needs, from library construction and gene identification to protein expression and purification.
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. Allos is currently focused on the development and commercialization of FOLOTYN (pralatrexate injection), a folate analogue metabolic inhibitor. FOLOTYN is the first and only drug approved in the United States for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Allos is also developing FOLOTYN in other hematologic malignancies and solid tumors. Allos retains exclusive worldwide rights to FOLOTYN for all indications. Allos is headquartered in Westminster, CO. For additional information, please visit their website.
Prolong Pharmaceuticals LLC
Prolong Pharmaceuticals, based in South Plainfield, NJ, is developing products targeting anemia resulting from oxygen deficiency. The company’s clinical development efforts are focused on sickle cell anemia, diabetic ischemia, and several trauma indications. Prolong is also advancing a long-acting third-generation biologic for treating anemia due to chronic kidney disease and cancer treatment. The company is privately owned and is managed by an experienced team of biopharmaceutical executives, including BIONJ’s original founder, Dr. Abraham Abuchowski.
BioNJ thanks Apicore LLC, Diehl Servilla LLC, Epsen Fuller/IMD, ESIS, Inc., and Huntingdon Life Sciences for renewing their Associate Memberships for 2012.
Apicore is a developer and manufacturer of specialty Active Pharmaceutical ingredients and c GMP advanced intermediates. Focus is on helping clients obtain timely approval of their ANDAs NDAs or marketing authorization applications.
Diehl Servilla LLC
Diehl Servilla provides services and counseling in all areas of intellectual property, including patent and trademark procurement, strategic development of portfolios, licensing and technology transfer, litigation, and preparation of opinions.
New Jersey-based Epsen Fuller/IMD International Search Group is among the world’s Top-20 retained executive search and consulting firms, with over 150 consultants and offices in all the major markets around the globe. With global reach, Epsen Fuller/IMD conducts assignments for senior-level and mid-management talent throughout the life sciences to include biotechnology, medical devices, and pharmaceuticals. The firm’s Performance-Based Assessment approach ensures superior talent acquisition, enabling clients to build a sustainable talent advantage.
ESIS Risk Control Service is a full-service environmental health safety and sustainability consulting firm who partners with clients to cost effectively manage EHS risk and positively contribute to the bottom line.
Huntingdon Life Sciences
In the world of product development and safety evaluation, Huntingdon Life Sciences is setting new industry standards. This is why many of the world’s leading pharmaceutical, biotechnology, chemical, and agrochemical companies ask us to help them to bring their products to market. We have vast expertise in a variety of scientific disciplines and offer comprehensive services in general and specialized toxicology.